Last €0.03 EUR
Change Today +0.002 / 7.69%
Volume 0.0
E4N On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:20 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

suda ltd (E4N) Snapshot

Open
€0.03
Previous Close
€0.03
Day High
€0.03
Day Low
€0.03
52 Week High
12/19/13 - €0.06
52 Week Low
09/12/13 - €0.01
Market Cap
27.5M
Average Volume 10 Days
1.0K
EPS TTM
--
Shares Outstanding
981.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUDA LTD (E4N)

Related News

No related news articles were found.

suda ltd (E4N) Related Businessweek News

No Related Businessweek News Found

suda ltd (E4N) Details

Suda Limited is involved in the pharmaceutical development of drug delivery technologies in Australia. The company is engaged in developing ArTiMist, a sub-lingual anti-malarial delivery system that completed Phase III trials to address the pre-referral and hospital based treatment of paediatric uncomplicated malaria with gastrointestinal complications, such as vomiting and diarrhea, and severe malaria; and SudaMist, a sub-lingual platform technology. It also distributes medical devices and consumables to hospitals, aged care facilities, allied health centers, mining customers, detention centers, general practices, day surgeries, and other healthcare providers. The company was formerly known as Eastland Medical Systems Limited and changed its name to Suda Limited in December 2012. Suda Limited is based in Osborne Park, Australia.

14 Employees
Last Reported Date: 09/27/13

suda ltd (E4N) Top Compensated Officers

Chief Executive Officer, Managing Director, D...
Total Annual Compensation: A$233.2K
Chief Financial Officer, Company Secretary, E...
Total Annual Compensation: A$106.2K
General Manager of Westcoast Surgical
Total Annual Compensation: A$100.0K
Compensation as of Fiscal Year 2013.

suda ltd (E4N) Key Developments

Suda Ltd Announces Resignation of Ken Robson as Director

Suda Ltd. announced that it has received and accepted the resignation of Mr. Ken Robson from the Board, effective August 7, 2014. Mr. Robson joined the company as a Non-Executive Director in March 2013 to provide legal guidance to the Board. During his tenure with the company, Mr. Robson has provided valuable, impartial legal opinions in relation to the operations of the company group.

Suda Ltd, Annual General Meeting, May 09, 2014

Suda Ltd, Annual General Meeting, May 09, 2014., at 10:30 W. Australia Standard Time. Location: The Boulevard Centre. Agenda: To consider the adoption of employee share option plan; to consider the adoption of employee performance rights plan; to consider the adoption of tax exempt plan; to consider the approval to issue options and/or performance rights to Mr. Stephen Carter, Mr. Joseph Ohayon and Mr. Michael Stewart; to ratify the prior issue of 169,132,089 shares; to ratify the prior issue of 10,224,698 shares to Bergen; to approve the issue of shares on conversion of the interest; and to approve the component on the 2013 convertible notes.

Suda Ltd Announces Appointment of Clinical Advisory Board for Malaria

Suda Ltd. announced the appointment of four leading malaria experts to its newly founded Clinical Advisory Board. SUDA's Clinical Advisory Board members are, Professor Tim Davis BMedSc, MB BS, DPhil, FRACP, FRCP - Professor at the School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Professor Ric Price MB (London), MA (Cambridge), BChir (Cambridge) - Professor of Global Health, the Menzies School of Health Research, Royal Darwin Hospital; and Professor of Tropical Medicine, the Centre of Tropical Medicine, University of Oxford, UK, Professor Kevin Marsh MBChB - Director of the Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya. Chair of the WHO Malaria Policy Advisory Committee (MPAC), and Dr. Stephen Rulisa, MD, MMed (Obs/Gyn) - Head of Obstetrics & Gynaecology, University of Rwanda, School of Medicine; and Principal Investigator for two clinical trials of ArTiMistTM, including the successful Phase III trial in children with severe malaria. These experts are providing advice and guidance to SUDA on the expansion of the market for ArTiMistTM beyond severe paediatric malaria. SUDA convened the inaugural meeting of its Clinical Advisory Board on 27 March 2014 to discuss the design of a pivotal Phase III trial of ArTiMistTM as an early interventional treatment in the pre-referral setting. SUDA does not intend to initiate further trials without a partner, but will present the protocol to the WHO and philanthropic funds that have indicated an interest in supporting further clinical evaluation of ArTiMistTM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
E4N:GR €0.03 EUR +0.002

E4N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for E4N.
View Industry Companies
 

Industry Analysis

E4N

Industry Average

Valuation E4N Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUDA LTD, please visit www.sudaltd.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.